FFL Flash Alert - With his Saints teammates getting healthy, the veteran TE could be in for a down game vs. SF.
FFL Flash Alert - With his Saints teammates getting healthy, the veteran TE could be in for a down game vs. SF.
Shares in Italy's UniCredit fell as much as 8% in early trade on Tuesday after Chief Executive Jean Pierre Mustier said he would leave at the end of his term in April due to divergences with the board over strategy. UniCredit announced late on Monday Chairman elect Pier Carlo Padoan and the board would start looking for a replacement. News of Mustier's departure comes on the backdrop of quickening consolidation in Italian banking, where the Treasury is looking for a buyer for bailed-out bank Monte dei Paschi.
Germany's benchmark 10-year bond yield hovered near three-week lows on Tuesday, while southern European debt yields kept record lows in sight ahead of inflation numbers expected to reinforce the case for more stimulus at next week's European Central Bank (ECB) meeting. Having risen in early November as news of a COVID-19 vaccine boosted hopes of recovery next year, government bond yields have drifted back down as global central bank officials have indicated stimulus will remain in place for some time.
The German was upset with the Reds’ schedule after featuring in the early kick-off on Saturday
COPENHAGEN, Denmark, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Nordea Bank Abp has on 30 November 2020 received a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which BlackRock, Inc.'s indirect shareholding of Nordea Bank Abp's shares and voting rights crossed the threshold of 5 per cent on 27 November 2020. According to the notification, the total number of Nordea Bank Abp's shares and voting rights held directly or through financial instruments by BlackRock, Inc. and its funds was 5.01 per cent on 27 November 2020.The total number of shares and voting rights in Nordea Bank Abp is 4,049,951,919.Total positions of BlackRock, Inc. and its funds: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A + B) Resulting situation on the date on which threshold was crossed or reached4.98%0.02%5.01% Position of previous notification (if applicable)N/AN/AN/A Notified details of the resulting situation on the date on which the threshold was crossed or reached:A: Shares and voting rightsClass/type of shares ISIN code (if possible) Number of shares and voting rights% of shares and voting rights Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7) FI4000297767 201,940,391 4.98% SUBTOTAL A201,940,391 4.98% B: Financial instruments according to SMA 9:6aType of financial instrumentExpiration dateExercise/ Conversion periodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rights Securities lentN/AN/APhysical55,5740.00% CFDN/AN/ACash1,114,4670.02% SUBTOTAL B1,170,0410.02% The controlled undertakings through which the shares, voting rights and financial instruments are effectively held:Name% of shares and voting rights% of shares and voting rights through financial instrumentsTotal of both BlackRock Japan Co., Ltd. Below 5% BlackRock Investment Management, LLC Below 5% BlackRock Investment Management (UK) Limited Below 5% BlackRock Investment Management (Australia) Limited Below 5% BlackRock International Limited Below 5% BlackRock Institutional Trust Company, National Association Below 5% BlackRock Fund Advisors Below 5% BlackRock Financial Management, Inc. Below 5% BlackRock Asset Management North Asia Limited Below 5% BlackRock Asset Management Deutschland AG Below 5% BlackRock Asset Management Canada Limited Below 5% BlackRock Advisors, LLC Below 5% BlackRock (Netherlands) B.V. Below 5% For further information: Matti Ahokas, Head of Investor Relations, +358 9 53008011 Group Communication, +358104168023 or firstname.lastname@example.orgThe information provided in this stock exchange release was submitted for publication, through the agency of the contact persons set out above, at 09:00 EET on 1 December 2020.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
Police have opened an investigation into the disappearance of a large wooden sculpture from a mountainside where it appeared without explanation years ago.
Bid date, 2020-12-01 Auction date2020-12-01 Settlement date2020-12-02 Maturity Date2020-12-09 Nominal amount380 billion SEK Interest rate, %0.00 Bid times09.30-10.00 (CET/CEST) on the Bid date Confirmation of bids to firstname.lastname@example.org The lowest accepted bid volume1 million SEK The highest accepted bid volume380 billion SEK Allocation Time10.15 (CET/CEST) on the Bid date Projected minimum liquidity surplus during the term844 billion SEK Expected excess liquidity at full allotment464 billion SEK Stockholm, 2020-12-01
Remote cardiac monitoring service Zio XT has been evaluated and positively recommended by NICESAN FRANCISCO and UNITED KINGDOM, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced it is the first technology to pass through a new digital health tech pilot, resulting in a successful recommendation for adoption from the National Institute for Health and Care Excellence (NICE). iRhythm’s Zio XT Service – a patient-friendly ambulatory cardiac monitor supported by deep learning algorithms – has been assessed as part of NICE’s first pilot project to evaluate digital health technologies. Zio XT has been positively recommended by NICE as an option for people with suspected cardiac arrhythmias who would benefit from ECG monitoring for longer than 24 hours.Published today, the guidance concluded that Zio XT is convenient and easy to wear, with greater patient compliance and improved diagnostic yield (a measure of how many people with cardiac arrhythmias are diagnosed) compared with standard 24-hour Holter monitoring. Clinical evidence showed that patients preferred Zio XT compared to current monitoring practice in the NHS, which usually involves wearing a continuous ECG monitor, such as the 24-hour Holter monitor. Estimates also suggest that using Zio XT is likely to be cost saving, or cost the same as using 24-hour Holter monitoring.Commenting on the news, Justin Hall, GM and VP EMEA at iRhythm said, “We are delighted that Zio has received such positive guidance from NICE in this first of its kind evaluation, especially at such a critical time. Throughout the COVID-19 pandemic we have seen a number of cardiac patients avoiding hospitals and suffering in silence, even when experiencing serious conditions such as strokes. This has led to a backlog of patients requiring care, putting additional pressure on medical staff and services.”“Fortunately, services like Zio can help ease this backlog, offering clinically-validated services remotely. Patients are not required to expose themselves to high-risk hospital environments, while staff can still offer the same continued level of care. It’s critical, therefore, that patients have access to these technologies and for clinicians to be able to implement them quickly and easily.”The guidance, which evaluates new, innovative medical devices and diagnostics, aims to help people in the NHS make efficient, cost-effective and consistent decisions about adopting new medical technologies. A positive NICE Medical Technologies Guidance opens the door for future support of the Zio service through the MedTech Funding Mandate, which aims to help accelerate the uptake of proven affordable innovations as part of the NHS Long Term Plan.iRhythm’s positive recommendation from the NICE digital health pilot builds on the company’s recent win of the UK government’s AI in Health and Care Award, in which iRhythm will utilise the funding to evaluate its Zio service in selected NHS sites across the UK. Throughout the three-year programme, clinical, pathway and economic outcomes will be monitored and evaluated in order to inform any future commissioning decisions around the adoption of Zio within the NHS.About iRhythm Technologies, Inc.iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distil data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.Media Contacts: Ellie Stansfield Hotwire for iRhythm Technologies email@example.comSaige Smith HighwirePR for iRhythm Technologies firstname.lastname@example.orgInvestor Relations Contact: Leigh Salvo Gilmartin Group email@example.com
Russian driver Nikita Mazepin has been signed to race for Haas on a multi-year deal, starting from the 2021 Formula One season.
Every Premier League fixture for the 2020/21 season plus confirmed dates and kick-off times
Kuick Research Reports Highlights Multiple Clinical & Clinical Aspects Related To Global Orphan Drug MarketDELHI, India, Dec. 01, 2020 (GLOBE NEWSWIRE) -- "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: * Global Orphan Drug Market Opportunity: US$ 300 Billion * US Dominates Global Orphan Drug Market: 50% Market Share * US Orphan Drug Opportunity To Surpass: US$ 150 Billion * Global Orphan Drug Clinical Insight: More Than 900 Drugs * Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs * Oncology To Dominate Orphan Drug Development: 35% Share * FDA & EMA Regulations For Orphan Drugs * Orphan Drug Designation Criteria & Reimbursement Policy by CountryFor Report Sample Contact: firstname.lastname@example.orgThe orphan drug market is dedicated to treating the disease conditions that are rare as well as life-threatening to small percentage of patient population at global level. As per witnessed for the global orphan drug market, it is analyzed that the overall cost of the development of orphan drugs is much higher than the drugs that are considered to be working against some of the common diseases such as cardiovascular diseases due to the less availability of the participants for the clinical trials and less drug numbers in the market. Such challenges observed in the orphan drug market is estimated to be taken into severe consideration by the government of different economically strong countries and with respect to this, to overcome supply chain issues hundreds of strategies and investment plans are encouraging the market to boost and meet the needs of the patient population.In the past few years, it can be observed that there has been an increase in the number of opportunities that are associated with the orphan drug makers as the drug makers involved in the market are focusing on expanding the drug policies and specifically product range for each and every rare disease conditions. The forthcoming years of the orphan drug market is estimated to observe increase in the research and development as well as overall business operations and outreach, increase in the patient rights, increase in orphan drug competition, healthcare solutions getting delivered by orphan drugs and increase in the number of investors at a splendid rate. In addition to all the above-mentioned parameters, increase in the number of drugs developed for rare blood diseases and uncured diseases are estimated to explore the global market growth towards bright future.There has been an increase in the number of research and development risks, which is aligning the market to hold true value towards the unstructured treatment paradigm for the patients who are suffering from rare disease. The future fragmentation of the market with respect to increase in competitive landscape is believed to be providing tough competition to the other traditional therapies. Specific changes being performed in the market with respect to policies and collaborations for exchanging expertise is also leading the market to adopt great dynamics in a shorter period of time.The global orphan drug market has led to the emergence of a transformation that is important when witnessed from public-health measures. The respective trifecta settled by the market is estimated to set up a market size in the future that will be robust and strong. The current state of the global orphan drugs in the pharmaceutical sector is estimated to determine and unravel the hidden parameters of the rare diseases that will make the researchers and the patients inclined towards the intense competition that the market is about to deliver. The analysis of the upcoming trends and opportunities associated with global the orphan drug market is estimated to deliver significant development across the therapeutics research and development across industry.As per report findings, it is estimated that the emergence of the market at a global level has led to a progressive shift in the current healthcare sector. Within a short period of time, the market is on the urge of providing an aligned structure to the therapeutics market as well as a broad perspective of potential and promising applications that is held by the market. The global research report with respect to the orphan drug market provides a deep comprehensive view about the dynamic forces that are driving the market as well as combination of opportunities, trends and challenges. In addition to all this, the report also provides a complete outlook of the market, the current profiles of the drugs and the timeline of the investigational drugs that are boosting the overall market.Contact: Neeraj chawla email@example.com +91-9810410366
President Donald Trump "needs to pardon his whole family and himself" as hewalks "out the door" of the White House, Fox News host Sean Hannity said onhis radio show Monday.
ANNOUNCEMENT NO. 107 - 1 DECEMBER 2020In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90.Kind regards,Dampskibsselskabet NORDEN A/SMartin BadstedCFOFor further information:Martin Badsted, CFO, tel.: +45 3315 0451Attachments * No. 107 Managers' transactions * Transactions by persons discharging managerial responsibilities and persons
F1 and Mercedes champ Lewis Hamilton will miss the Sakhir Grand Prix after it was confirmed he had tested positive for Covid-19.
Australian driver Oscar Piastri is just one step away from Formula One after Italian team PREMA Racing confirmed he'll compete in Formula Two next year.
Curved Walls of Channel Glass Create Circular Flow through the Office and Facilitate Physical Separation FlightHub Office, Montreal, QC by ACDF Architecture. Photo by DiVETRO (installer). FlightHub Office, Montreal, QC by ACDF Architecture. Photo by Maxime Brouillet.NEW YORK, NY, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bendheim’s newest case study reveals the intended and unexpected benefits of its curved channel glass wall design at the new FlightHub Office by ACDF Architecture. The daylight and privacy-friendly circular channel glass partition creates an efficient flow that facilitates social distancing. The translucent glass separates the space while maintaining a sense of connectivity. The 18-page publication details how the double-glazed channel glass wall solution addresses the design challenges. The case study includes sections dedicated to budget-friendly design, sustainability, and acoustic, visual, and physical privacy. Feedback from the architect and installer describes the collaborative aspect of the design, while Bendheim’s detail drawings illustrate how the channel glass maps into the layout and ties into other systems. Approximately twenty images bring the FlightHub office design to life.Channel glass is a translucent, three-dimensional, textured glass produced in several widths ranging from 9″ to 19″ and lengths up to 23 feet. Its signature U-channel shape adds great strength and makes it self-supporting, allowing it to create long uninterrupted spans of glass with minimal framing elements.Bendheim’s double-glazed walls are formed of rows of individual glass channels, facing one another – flanges in. The flanges create a cavity that is filled with air or insulation inserts, providing outstanding acoustic properties. The textured glass obscures views through the wall, while transmitting soft, diffused light. Channel glass walls are ideal for privacy and daylighting applications – a contemporary solution for the new challenges office designers face today.To read the case study and learn more about channel glass design for interiors, please visit https://bendheim.com/professional/resources/additional-readings/.Attachments * flighthub-curved-channel-glass-office-walls-1 * flighthub-curved-channel-glass-office-walls-pro1 CONTACT: Thomas Renner Catalyst Marketing Communications, Inc. 203-348-7541 firstname.lastname@example.org
The Swiss government will issue bonds with a face value of 6.5 billion Swiss francs ($7.17 billion) next year, the Swiss National Bank said on Tuesday, increasing the total amount of outstanding bonds by 2.4 billion francs.
Arsenal captain Pierre-Emerick Aubameyang has been tipped to leave the club next summer if Mikel Arteta's tactics don't change. Aubameyang was instrumental for the Gunners' FA Cup win last season as Arteta won his first trophy as manager, following up soon after with the Community Shield. Paul Ince is concerned about Aubameyang's happiness, despite signing a three-year extension over the summer, with Arteta's tactics stiffling his attacking output.
Reference is made to the stock exchange notice of 1 December regarding shares for employees 2020.Employees in Grieg Seafood have been offered to buy GSF ASA shares at a 20 % discount, for alternatively NOK 8 000, NOK 12 000 or NOK 20 000 (after discount). The gross purchase price was the volume-weighted average share price of NOK 77,16 per share as traded on Oslo Børs in the period between 17 November to 30 November 2020.As a part of the share purchase program for employees in 2020, the following primary insiders have purchased Grieg Seafood ASA shares:Andreas Kvame, CEO, purchased 324 shares. After the transaction he holds 39 489 shares.M. N. Kathleen Offman Mathisen, CHRO, purchased 324 shares. After the transaction she holds 12 060 shares.Knut Utheim, COO, purchased 324 shares. After the transaction he holds 23 831 shares.Atle Harald Sandtorv, CFO, purchased 324 shares. After the transaction he holds 24 532 shares.Roy-Tore Rikardsen, COO Farming North America, purchased 324 shares. After the transaction he holds 19 889 sharesAlexander Knudsen, COO Farming Europa, purchased 324 shares. After the transaction he holds 22 489 shares.Erik Holvik, CCD, purchased 324 shares. After the transaction he holds 324 sharesKristina Furnes, GCM, purchased 324 shares. After the transaction she holds 324 sharesTrude Elisabeth Østvedt, CAO, purchased 324 shares. After the transaction she holds 489 shares.Renete Kaarvik, GFO, purchased 324 shares. After the transaction she holds 489 shares. For further information, please contact: * CFO Atle Harald Sandtorv (cell phone +47 908 45 252) About Grieg Seafood ASAGrieg Seafood ASA is one of the world's leading salmon farmers. Our farms are in Finnmark and Rogaland in Norway, British Columbia and Newfoundland in Canada, and Shetland in the UK. Our headquarter is located in Bergen, Norway. Grieg Seafood was listed at the Oslo Stock Exchange in June 2007. More than 900 people are employed by the company globally.Sustainable farming practices are the foundation of Grieg Seafood's operations. The lowest possible environmental impact and the best possible fish welfare drive economic profitability. Towards 2025, we aim for global growth, cost leadership in each region and to evolve from a pure salmon supplier to an innovation partner for selected customers.To learn more, please visit www.griegseafood.com. This information is subject of the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act
Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Global AI-Enabled Imaging Modalities Market: 12 Countries Analysis - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering. Global AI-Enabled Imaging Modalities Market to Reach $2.64 Billion by 2030 Global AI-enabled imaging modalities market is currently witnessing a significant change in the market landscape. There is a rising investment in the development of healthcare infrastructure, increasing evidence for efficient and promising results in treatment and diagnosis assistance. Thus, this is leading to potential growth opportunities for the AI-enabled imaging modalities market. Moreover, there is an extensive entry of emerging players developing AI-powered imaging systems, and software companies into the healthcare space. All these predominant factors have led to a significant rise in sales of AI-based imaging modality systems across the globe.Global AI-Enabled Imaging Modalities Market Forecast, 2020-2030The global AI-enabled imaging modalities market was valued at $214.4 million in 2019 and is anticipated to reach $2,649.6 million by 2030, growing at a CAGR of 23.32%, during the forecast period 2020-2030. The increasing complexities in clinical decision making, rising radiologist workload, and huge R&D investments are the major factors fueling market growth. In addition to these factors, there are significant challenges and restraints, which are restricting market growth. These challenges include the physicians' reluctance toward the adoption of advanced technologies such as AI and the privacy and security concerns related to healthcare data. Hence, it is anticipated that these trends will have a significant impact on healthcare service robots market in the next five years, and the market will grow multifold.Competitive LandscapeThe global AI-enabled imaging modalities market consists of numerous large-scale as well as small-scale manufacturers and vendors. Presently, with the increasing adoption of AI in healthcare, the manufacturers in the market have an ample number of opportunities to expand their offerings and to establish a strong foothold in the market.During February 2016-July 2020, the market witnessed approximately 40 new offerings, 32 partnerships, alliances & business expansions, 27 regulatory & legal approvals, 13 funding activities, six mergers & acquisition, and one procurement & sales.Most of the manufacturers in the market are incorporating collaborations and partnerships with not only other companies but also the university and research institutions as the key strategies to develop novel AI-embedded medical imaging systems and attain a strong financial position in the market.Key Topics Covered: 1 Product Definition2 Research Scope3 Research Methodology4 Industry Insights 4.1 Industry Ecosystem 4.2 Regulatory Framework 4.2.1 North America 18.104.22.168 Regulatory Requirements in U.S. 22.214.171.124 Regulatory Requirements in Canada 4.2.2 Europe 4.2.3 Other Countries 4.3 Impact of COVID-19 4.3.1 Impact on Clinical Settings and Clinical Decision-Making 4.3.2 Impact on AI-Based Imaging Modality Manufacturers 4.3.3 Conclusion5 Competitive Landscape 5.1 Key Developments and Strategies 5.1.1 New Offerings 5.1.2 Partnerships, Alliances, and Business Expansions 5.1.3 Regulatory and Legal Approvals 5.1.4 Funding Activities 5.1.5 Mergers and Acquisitions 5.1.6 Procurement and Sales 5.2 Market Share Analysis 5.2.1 Market Share Analysis: Global AI-Enabled Imaging Modalities Market (Imaging Modality Providers) 5.3 Growth Share Analysis 5.3.1 Growth Share Matrix (by Modality) 5.3.2 Growth Share Matrix (by Workflow) 5.3.3 Growth Share Matrix (by Therapeutic Application)6 Global AI-Enabled Imaging Modalities Market Scenario 6.1 Assumptions and Limitations 6.2 Global AI-Enabled Imaging Modalities Market Size and Forecast 6.3 Potential Opportunities - AI-Enabled Imaging Modalities 6.3.1 Standardization of Radiology Practice 6.3.2 Voluminous Medical Imaging Data Requiring Analysis 6.3.3 Decline in Imaging Reimbursement Forcing Facilities for Accelerated and Accurate Performance 6.3.4 Increasing Participation 6.4 Market Dynamics 6.4.1 Impact Analysis 126.96.36.199 Impact Analysis of Market Drivers and Market Restraints, 2019-2030 6.4.2 Market Drivers 188.8.131.52 Need for Personalized and Standardized Patient-Centric Care 184.108.40.206 Accurate and Rapid Diagnosis Enabled by Artificial Intelligence 220.127.116.11 Increasing Workload of Radiologists 18.104.22.168 Evolving Hardware Technologies and Data Quality 6.4.3 Market Restraints 22.214.171.124 Lag in Regulatory Approvals 126.96.36.199 Legal Implications of AI Systems 188.8.131.52 Rise in Medical Imaging Expenses 184.108.40.206 Data Security and Privacy Issues 220.127.116.11 Lack of Trained Staff 6.5 Key Vendors7 Global AI-Enabled Imaging Modalities Market (by Modality) 7.1 Overview 7.2 Computed Tomography (CT) 7.3 Magnetic Resonance (MR) 7.4 Ultrasound 7.5 X-Ray 7.6 Positron Emission Tomography (PET) 7.7 Other Modalities8 Global AI-Enabled Imaging Modalities Market (by Workflow), 2019-2030 8.1 Overview 8.2 Image Acquisition 8.3 Image Analysis 8.4 Detection 8.5 Diagnosis and Treatment Decision Support 8.6 Predictive Analysis and Risk Assessment 8.7 Triage 8.8 Reporting and Communication9 Global AI-Enabled Imaging Modalities Market (by Therapeutic Application) 9.1 Overview 9.2 Cardiology 9.3 Oncology 9.3.1 Breast Cancer 9.3.2 Lung Cancer 9.3.3 Other cancer types 9.4 Neurology 9.5 Pulmonology 9.6 Others10 Global AI-Enabled Imaging Modalities Market (by Region)11 Company Profiles * Agfa-Gevaert Group * Butterfly Network, Inc. * Canon, Inc. * Exo * Fujifilm Holdings Corporation * General Electric Company * Hologic, Inc. * Hyperfine * Konica Minolta, Inc. * Koninklije Philips N.V. * Nanox * Siemens Healthineers AG * Tissue Differentiation Intelligence, LLC (TDi) * United Imaging Healthcare * Yor Labs, Inc.For more information about this report visit https://www.researchandmarkets.com/r/32di53Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Japan will consider giving subsidies and tax breaks to small and mid-sized enterprises (SMEs) to help them restructure and adjust to a post-coronavirus world, an interim report of the government's economic growth strategy showed on Tuesday. The government should also consider extending until March a zero-interest-rate loan scheme aimed at easing corporate funding strains that expire this month, the report said. The interim report, which is usually released in December each year and was presented at the Growth Strategy Council on Tuesday, said specific steps should be taken to promote mergers and acquisitions as well as business transformation of SMEs.